From Financial Modeling Prep: 2025-04-04 15:53:00

UBS reaffirmed its Buy rating on Johnson & Johnson (NYSE:JNJ) with a $180 price target, citing short-term volatility risks due to a recent legal setback in talc litigation. Despite rejection of bankruptcy proceedings, UBS remains confident in J&J’s fundamentals for 2025, highlighting the impact of Medicare Part D redesign and positive growth drivers.

UBS analysts note the potential growth from the acquisition of Intra-Cellular Therapies (ITCI) and steady performance amid the loss of exclusivity on Stelara. Investor focus will be on earnings implications for certain drugs, with Tremfya showing promise with 14% quarter-over-quarter growth in total prescriptions, especially in ulcerative colitis (UC) and upcoming launch in Crohn’s disease (CD).

While near-term uncertainty exists, UBS sees J&J’s broad pipeline, ongoing innovation, and defensive business mix as key factors for longer-term upside. Despite short-term sentiment tied to earnings, Tremfya’s performance and unique dosing regimen position J&J well for future growth.



Read more at Financial Modeling Prep:: Johnson & Johnson Faces Pressure to Deliver After …